L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites

The efficacy of anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) treatment with small molecule inhibitors is greatly challenged by acquired resistance. A recent study reported the newest generation inhibitor resistant mutation L1198F led to the resensitization to crizotin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Sun, Rong, Wu, Yuehong, Song, Mingzhu, Li, Jia, Yang, Qianye, Chen, Xiaoyi, Bao, Jinku, Zhao, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372498/
https://www.ncbi.nlm.nih.gov/pubmed/28245558
http://dx.doi.org/10.3390/ijms18030482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372498/
https://www.ncbi.nlm.nih.gov/pubmed/28245558
http://dx.doi.org/10.3390/ijms18030482

Ejemplares similares